4D Molecular Therapeutics, Inc. Common Stock (FDMT) — Analysis Summary
4D Molecular Therapeutics, Inc. Common Stock (FDMT) has a market cap of $518.06M with year-over-year revenue growth of +230194.6%. Net margin stands at -164.4%. The stock trades at a P/E ratio of -3.2.
Key Takeaways
- Revenue changed +230194.6% year-over-year
- Net margin of -164.4%
- P/E ratio of -3.2
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, FDMT posted revenue growth of +230194.6% and trades at a P/E of -3.2.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.